spacer
home > ict > winter 2017 > weave the threads
PUBLICATIONS
International Clinical Trials

Weave the Threads

Pharmaceutical companies do some of the most innovative and ground-breaking work in the world. Scientists, by thinking differently to uncover new approaches and building new understanding, quite literally change millions of lives for the better through new disease therapies. Bringing to market the valiant work of these forward-thinking professionals and converting a theoretical therapy into a safe and effective drug is not as easy as it may seem when we look at a pristine white tablet in our hand.

Rightfully, the prescription and commercial distribution of medicinal products, as well as the administration of drug products to patients in a clinical trial setting, are heavily regulated. These guidelines have their origins in periods throughout the recent past where there was little or no control over therapies; there are numerous cases of serious harm and even death of patients and consumers innocently looking for the benefits of so-called medicine without awareness of potential risks. After all, much of what is considered curative in low doses is actually poisonous or toxic at higher doses. Every product must be considered in light of the very fine balance of the associated risk-benefit to the patient. Health agencies and the pharma sector are constantly striving to improve the regulatory process as they continuously work to provide safe and efficacious use of medicines.

While these protocols are necessary to ensure the safety and efficacy of new drugs and the ethical business practices across the industry, the burden of compliance may, in many cases, delay and complicate the process of bringing new therapies to market. What a shame it is that the same level of innovation applied to R&D has not yet appropriately and broadly been applied to easing the compliance liability.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Evjatar Cohen is an experienced pharmaceutical executive with an extensive background in developing global business portfolios, including new products, technologies and intellectual property. As Global Practice Leader for pharmaceuticals at Appian, he is responsible for client success and continued steady growth in licence revenues across all pharma clients. Evjatar previously worked for Catalent as Vice President of Global Innovation. He holds an MBA in Pharmaceutical Management, an MS in Biotechnology and a BS in Chemistry.
spacer
Evjatar Cohen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PM Group Worldwide Ltd and The Datateam Media Group announce acquisition of Samedan Ltd

PMGroup Worldwide Ltd and The Datateam Media Group are pleased and excited to announce the acquisition of pharmaceutical publishers Samedan Ltd. The deal brings together three publishing powerhouses in the pharmaceutical and healthcare sector - with Samedan joining PMGroup and PharmaTimes Media Ltd as part of The Datateam Media Group’s healthcare division.
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement